Vanda Pharmaceuticals | VNDA - Umsatzkosten





Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Anika Therapeutics USD 11.44M 797K 2025-12
AstraZeneca USD 2.52B 2.73B 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Heron Therapeutics USD 11.12M 795K 2025-12
Insmed USD 69.29M 19.79M 2026-06
J&J USD 8B 67M 2026-06
Lexicon Pharmaceuticals USD 201K 191K 2025-12
Ligand Pharmaceuticals USD 11.31M 59K 2026-06
Merck USD 3.14B 200M 2026-06
Minerva Neurosciences 386K 31K 2024-06
Moderna USD 93M 862M 2026-06
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.09B 498M 2026-06
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.02B 656M 2026-06
Takeda JPY 517.6B 42.94B 2026-06
Teva Pharmaceutical Industries USD 1.98B 30M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Veracyte USD 42.19M 3.7M 2026-06